Loading…

Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study

Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish register...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2017-10, Vol.46 (7), p.673-680
Main Authors: Bang, U. C., Benfield, T., Bendtsen, F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3
cites cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3
container_end_page 680
container_issue 7
container_start_page 673
container_title Alimentary pharmacology & therapeutics
container_volume 46
creator Bang, U. C.
Benfield, T.
Bendtsen, F.
description Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate. Results A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death. Conclusions Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis. Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.
doi_str_mv 10.1111/apt.14243
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1936622509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1936208281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</originalsourceid><addsrcrecordid>eNp10ctqGzEUBmBREhrH7aIvUATdJItxdJmLtDSmSQuBlJKuB43mGCsdS1OdGYx3fYKQZ8yTVPakXRSijW4fP0I_IR84W_A0rkw_LHgucvmGzLgsi0wwWZ6QGROlzoTi8oycIz4wxsqKibfkTCilWJ7rGXn8Du1ooaXR4U8a1rQFG7Y9eDSDC54a36YjM2yoQQzWmSHZnUv7EeHgcUjQI3We9mkFfsDp3nQ2bELnLLUuxk1Ahwu6pP6Yu3MtUGsQnn8_HVgcUtDY7t-R07XpEN6_zHPy4_rz_epLdnt383W1vM2sVEpmeVPoqoEKGrXmWum8EqaogGuRvkFXhWlyISwDpW0pGsMaowopSrCyLcAqI-fkYsrtY_g1Ag711qGFrjMewog117IshSiYTvTTf_QhjNGn1x2VYOrww3NyOSkbA2KEdd1HtzVxX3NWH0qqU0n1saRkP74kjs0W2n_ybysJXE1g5zrYv55UL7_dT5F_AHYjnfc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1936208281</pqid></control><display><type>article</type><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><source>Wiley</source><creator>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</creator><creatorcontrib>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</creatorcontrib><description>Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate. Results A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death. Conclusions Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis. Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14243</identifier><identifier>PMID: 28880449</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Cirrhosis ; Classification ; Cohort analysis ; Cohort Studies ; Data processing ; Death ; Female ; Females ; Health risk assessment ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Liver cirrhosis ; Liver Cirrhosis, Alcoholic - drug therapy ; Male ; Middle Aged ; Mortality ; Propensity Score ; Retrospective Studies ; Statins</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2017-10, Vol.46 (7), p.673-680</ispartof><rights>2017 John Wiley &amp; Sons Ltd</rights><rights>2017 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2017 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</citedby><cites>FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</cites><orcidid>0000-0003-0696-6124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28880449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bang, U. C.</creatorcontrib><creatorcontrib>Benfield, T.</creatorcontrib><creatorcontrib>Bendtsen, F.</creatorcontrib><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate. Results A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death. Conclusions Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis. Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</description><subject>Adult</subject><subject>Aged</subject><subject>Cirrhosis</subject><subject>Classification</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Data processing</subject><subject>Death</subject><subject>Female</subject><subject>Females</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis, Alcoholic - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Propensity Score</subject><subject>Retrospective Studies</subject><subject>Statins</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp10ctqGzEUBmBREhrH7aIvUATdJItxdJmLtDSmSQuBlJKuB43mGCsdS1OdGYx3fYKQZ8yTVPakXRSijW4fP0I_IR84W_A0rkw_LHgucvmGzLgsi0wwWZ6QGROlzoTi8oycIz4wxsqKibfkTCilWJ7rGXn8Du1ooaXR4U8a1rQFG7Y9eDSDC54a36YjM2yoQQzWmSHZnUv7EeHgcUjQI3We9mkFfsDp3nQ2bELnLLUuxk1Ahwu6pP6Yu3MtUGsQnn8_HVgcUtDY7t-R07XpEN6_zHPy4_rz_epLdnt383W1vM2sVEpmeVPoqoEKGrXmWum8EqaogGuRvkFXhWlyISwDpW0pGsMaowopSrCyLcAqI-fkYsrtY_g1Ag711qGFrjMewog117IshSiYTvTTf_QhjNGn1x2VYOrww3NyOSkbA2KEdd1HtzVxX3NWH0qqU0n1saRkP74kjs0W2n_ybysJXE1g5zrYv55UL7_dT5F_AHYjnfc</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Bang, U. C.</creator><creator>Benfield, T.</creator><creator>Bendtsen, F.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0696-6124</orcidid></search><sort><creationdate>201710</creationdate><title>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</title><author>Bang, U. C. ; Benfield, T. ; Bendtsen, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cirrhosis</topic><topic>Classification</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Data processing</topic><topic>Death</topic><topic>Female</topic><topic>Females</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis, Alcoholic - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Propensity Score</topic><topic>Retrospective Studies</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bang, U. C.</creatorcontrib><creatorcontrib>Benfield, T.</creatorcontrib><creatorcontrib>Bendtsen, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bang, U. C.</au><au>Benfield, T.</au><au>Bendtsen, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2017-10</date><risdate>2017</risdate><volume>46</volume><issue>7</issue><spage>673</spage><epage>680</epage><pages>673-680</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary Background Reports have indicated that the use of statins may ameliorate the course of cirrhosis. Aim To determine the relationship between use of statins and mortality rate in patients with cirrhosis. Methods We did a retrospective case‐cohort analysis based on data from the Danish registers from the period 1995 through 2014. Index date was time of diagnosis of cirrhosis (ICD‐10: K703) and cohort entry depended on whether the patient was statin user or not. We used propensity score matching with a statin:non‐statin ratio of 1:2. We included the exposure to statins (ATC classification C10AA) from the index date until death or end of follow‐up based on prescription claims. Use of statins based on at least two statin claims as well as the longitudinal pattern over time of statin claims was tested against mortality. The main outcome was mortality rate. Results A total of 24 748 patients with alcoholic cirrhosis were identified and 5417 were eligible for matching. The mean age was 56 (SD 10) years and 36% were females. The prevalence of use of statins was 15%. We included 744 in the matched cohort. Mortality rates were 88 (95% CI 73‐105) per 1000 years for patients using statin and 127 (95% CI 114‐141) for non‐statin patients with a HR of 0.57 (95% CI 0.45‐0.71). A more regular pattern of statin claims was related to a lower risk of death. Conclusions Our results showed an association between regular use of statins and reduced mortality in patients with alcoholic cirrhosis. Linked ContentThis article is linked to R. Huang et al and J. Wang and Mücke and Athyros et al and Zhao et al and Bang et al papers. To view these articles visit https://doi.org/10.1111/apt.14277, https://doi.org/10.1111/apt.14281, https://doi.org/10.1111/apt.14355, https://doi.org/10.1111/apt.14357 and https://doi.org/10.1111/apt.14364.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28880449</pmid><doi>10.1111/apt.14243</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0696-6124</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2017-10, Vol.46 (7), p.673-680
issn 0269-2813
1365-2036
language eng
recordid cdi_proquest_miscellaneous_1936622509
source Wiley
subjects Adult
Aged
Cirrhosis
Classification
Cohort analysis
Cohort Studies
Data processing
Death
Female
Females
Health risk assessment
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Liver cirrhosis
Liver Cirrhosis, Alcoholic - drug therapy
Male
Middle Aged
Mortality
Propensity Score
Retrospective Studies
Statins
title Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case‐cohort study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T04%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20risk%20of%20decompensation%20and%20death%20associated%20with%20use%20of%20statins%20in%20patients%20with%20alcoholic%20cirrhosis.%20A%20nationwide%20case%E2%80%90cohort%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Bang,%20U.%20C.&rft.date=2017-10&rft.volume=46&rft.issue=7&rft.spage=673&rft.epage=680&rft.pages=673-680&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14243&rft_dat=%3Cproquest_cross%3E1936208281%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3883-4b597be7eb8f1989472a57e192142975ab422c0e89c62ba0ba85326ec3d5ec8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1936208281&rft_id=info:pmid/28880449&rfr_iscdi=true